Clinical trial

A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide

NCT00671424

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Hydrochlorothiazide (HCTZ) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Remogliflozin etabonate (GSK189075) Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Furosemide Normalized identity: furosemideView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-03-01

PhasePHASE1

Conditions

Type 2 Diabetes Mellitusverified · MONDO: type 2 diabetes mellitus

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Interventions

Hydrochlorothiazide (HCTZ)DRUG

Remogliflozin etabonate (GSK189075)DRUG

FurosemideDRUG · verified · RxNorm: furosemide

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Mapped research locations

ColumbusOhio, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00671424 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.